Abstract：Objective To compare and analyze the effects of Entecavir and Tenofovir Disoproxil Fumarate in the treatment of chronic hepatitis B and liver cirrhosis patients. Methods A retrospective selection of 109 patients with chronic hepatitis B and liver cirrhosis admitted to Jilin Province Faw General Hospital from December 2018 to December 2020, they were divided into Entecavir (ETV） group (55 cases) and Tenofovir Disoproxil Fumarate (TDF) group (54 ceses) according to their treatment methods. Blood calcium (Ca), blood phosphorus (P), estimated glomerular filtration rate (eGFR) and bone mineral density (BMD) were collected before treatment (T0), 24 weeks after treatment (T1), 48 weeks after treatment (T2), and 96 weeks after treatment (T3), and the clinical significance of changes in Ca, P, eGFR and BMD were analyzed and compared. Results The time point difference of Ca between the two groups was statistically significant (P ＜ 0.05). There was no significant difference in P at time point, between groups and interaction (P ＞ 0.05). The time point and interaction of eGFR showed statistically significant differences (P ＜ 0.05), but there was no statistically significant difference between groups (P ＜ 0.05). Further pairwise comparison, intra-group comparison: Ca decreased at T3 compared with T0, and eGFR decreased at T1, T2, and T3 in TDF group compared with T0, with statistical significances (P ＜ 0.05). The time comparison of femoral neck bone mineral density and lumbar vertebra bone mineral density between the two groups had statistical significances (P ＜ 0.05). Further pairwise comparison showed that lumbar bone mineral density in TDF group was lower than that in ETV group at T2 and T3, with statistical significances (P ＜ 0.05). Conclusion ETV and TDF in the treatment of patients with hepatitis B and cirrhosis of the liver, the two drugs is not obvious effect on Ca, P, patients with the extension of treatment time of TDF affect the eGFR, TDF bone mineral density of patients treated by TDF is higher than ETV, and both the mean bone density decrease, as the treatment time extended effect is not obvious, and provide the basis for clinical doctor standard antiviral treatment for a long time.
付广双 申恩华 王茉莉 李欣杉 袁艺萌 吴阳. 恩替卡韦、富马酸替诺福韦二吡夫酯片治疗慢性乙型肝炎及其肝硬化的效果比较[J]. 中国医药导报, 2021, 18(35): 121-124.
FU Guangshuang SHEN Enhua WANG Moli LI Xinshan YUAN Yimeng WU Yang. Effect comparison of Entecavir and Tenofovir Disoproxil Fumarate in the treatment of chronic hepatitis B and liver cirrhosis#br#. 中国医药导报, 2021, 18(35): 121-124.
[1] 申恩华，王茉莉，王立红，等.恩替卡韦和替诺福韦二吡呋酯治疗慢性乙型肝炎及乙型肝炎肝硬化抗病毒效果[J].中国医药导报，2018，15（28）：70-73.
[2] 张维璐，吉兆华，付婷，等.中国2007-2016年59岁以下普通人群HBsAg阳性率的Meta分析[J].中华流行病学杂志，2017，38（9）：1278-1284.
[3] 中华医学会感染病学分会，中华医学会肝病学分会.慢性乙型肝炎防治指南（2019版）[J].肝脏，2019，24（12）：1335-1356.
[4] Luxon BA. Bone disorders in chronic liver diseases [J].Curr Gastroenterol Rep，2018，13（1）：40-48.
[5] 包雪梅，张剑.恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效分析[J].国际感染杂志：电子版，2020，9（1）：106.
[6] Sriprayoon T，Mahidol C，Ungtrakul T，et al. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients：A randomized controlled trial [J]. Hepatol Res，2017，47（3）：E161-E168.
[7] 徐勇，余琼华，黎鹏，等.替诺福韦与恩替卡韦初始治疗慢性乙肝患者的疗效比较[J].湖北科技学院学报：医学版，2021，35（1）：37-39，43.
[8] 宛月，孟岩，陈卓，等.健脾疏肝方联合恩替卡韦治疗乙型肝炎肝硬化的临床效果[J].广西医科大学学报，2021， 38（1）：150-155.
[9] 刘国平，俞慧.恩替卡韦联合复方甘草酸苷片治疗乙肝或肝硬化的效果及对患者肝纤维化指标、生活质量的影响[J].中国实用医药，2021，16（8）：140-142.
[10] 顾生旺，吴德平，李荣清.恩替卡韦联合或序贯干扰素治疗慢性乙型肝炎的现状、问题与前景[J].世界华人消化杂志，2016，24（18）：2799-2810.
[11] 肖丽，李阳，耿爱文，等.替诺福韦酯和恩替卡韦治疗慢性乙型肝炎的疗效和安全性的、Meta分析[J].中华传染病杂志，2015，33（10）：615-620.
[12] 王浩，常彩芳，范敬静.替诺福韦酯治疗合并非酒精性脂肪肝的慢性乙型肝炎患者的疗效[J].实用医学杂志，2018，34（11）：1795-1799.
[13] Yip TC，Wong VW，Chan HL，et al. Tenofovir is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China [J]. Gastroenterology，2020，158（1）：215-225.
[14] 周昌静，罗杰，崇雨田，等.替诺福韦酯初始单药治疗慢性乙型肝炎患者5年疗效分析[J].中山大学学报：医学科学版，2018，39（5）：710-716.
[15] 刘洁，漆俊，胥富波.富马酸替诺福韦酯单药长期治疗多药耐药慢性乙型肝炎患者的临床疗效及安全性分析[J].解放军医药杂志，2018，30（7）：64-67.
[16] 姚路静，昝松波，姬红波，等.替诺福韦挽救治疗耐药复发的慢性乙型肝炎的临床疗效[J].慢性病学杂志，2020，21（9）：1339-1341.
[17] 孙宏，刘冰，肖婷婷.富马酸替诺福韦二吡呋酯治疗乙型肝炎肝硬化临床评价[J].中国药业，2021，30（6）：80-82.
[18] Han Y，Zeng A，Liao H，et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis：A systematic review and Meta-analysis [J]. Int Immunopharmacol，2017，42：168-175.
[19] Lee HY，Oh H，Park CH，et al. Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B：Systematic review with meta-analysis [J]. World J Gastroenterol，2019，25（23）：2961-2972.
[20] 何艳杰，张程，王宇，等.恩替卡韦对轻度肾功能损伤慢性乙型肝炎患者eGFR的影响[J].临床和实验医学杂志，2016，15（18）：1818-1821.
[21] 王宇，张程，李红艺，等.恩替卡韦长期抗病毒治疗慢性乙型肝炎对患者肾脏功能的影响[J].临床和实验医学杂志，2017，16（15）：1502-1505.
[22] 李新文，范玉琛，邢延清，等.阿德福韦酯联合拉米夫定治疗慢性乙肝和肝硬化致肾损害的特点及处理探讨[J].中国医药导报，2019，514（20）：164-167.
[23] 张东矗，邓敦，童郁，等.慢性乙肝患者伴骨质疏松症的危险因素研究[J].中华全科医学，2020，18（3）：432-434， 445.
[24] Lopez-Lopez J，Lopez-Jaramillo P，Camacho PA，et al. The Link between Fetal Programming，Inflammation，Muscular Strength，and Blood Pressure[J].Mediators Inflamm，2015：710613. DOI：10.1155/2015/710613.
[25] 王三杏，谢雍，董矜，等.成人骨密度与慢性炎症的相关性分析[J].标记免疫分析与临床，2016，23（7）：717-721.
[26] Boron D，Kami■ski A，Kotrych D，et al. Polymorphism of vitamin D3 receptor and its relation to mineral bone density in perimenopa-usal woen [J]. Osteo Int，2015，26（3）：1045-1052.
京公网安备 11010502046598号